Tags

Type your tag names separated by a space and hit enter

Five year follow-up after primary vaccination against tick-borne encephalitis in children.
Vaccine. 2015 Apr 08; 33(15):1824-9.V

Abstract

BACKGROUND

A first tick-borne encephalitis (TBE) vaccine booster in children is currently suggested 3 years after completing either a conventional (doses on Days 0, 28 and 300) or accelerated conventional (doses on Days 0, 14 and 300) TBE immunization schedule. This recommendation, however, may not be appropriate in cases where different TBE vaccines have been used interchangeably during the primary immunization series.

METHODS

To provide robust data to better inform such recommendations, TBE antibody persistence was evaluated after 3-5 years in four groups of children (aged 5-15 years): two groups previously primed with three doses of Encepur(®) Children (conventional/accelerated conventional schedule); and two groups previously primed with two doses of FSME-IMMUN(®) followed by a third dose of Encepur(®) Children (conventional/accelerated conventional schedule). Immunogenicity was evaluated using neutralization (NT) assays based on both vaccine antigens as well as on the Enzyme Linked Immunosorbent Assay (ELISA).

RESULTS

In the two Encepur(®) Children groups (full series), protective NT titers of ≥10 were detected in 98-100% of children up to 5 years after their last primary vaccination, irrespective of schedule. In contrast, only 65-70% subjects in the FSME-IMMUN(®) Junior groups (mixed series) displayed NT titers ≥10 after 3 years. Thus, due to lower probability of achieving/maintaining long-term protective antibody levels (recently defined by the World Health Organization as an NT titer ≥10) after this time point, both FSME-IMMUN Junior groups were discontinued.

CONCLUSION

A strong antibody response persists for at least 5 years after full primary vaccination with Encepur(®) Children. The study thus provides support for extending the time interval for a first booster dose after primary vaccination (conventional/accelerated conventional schedule) with Encepur(®) Children from 3 to 5 years.

Authors+Show Affiliations

Am Bachlanger 3, D-82362 Weilheim, Germany.Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, USA.Novartis Vaccines and Diagnostics GmbH, Marburg, Germany.Novartis Vaccines and Diagnostics GmbH, Marburg, Germany.Novartis Vaccines and Diagnostics, Srl., Siena, Italy. Electronic address: elena.fragapane@novartis.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25728316

Citation

Wittermann, Christoph, et al. "Five Year Follow-up After Primary Vaccination Against Tick-borne Encephalitis in Children." Vaccine, vol. 33, no. 15, 2015, pp. 1824-9.
Wittermann C, Izu A, Petri E, et al. Five year follow-up after primary vaccination against tick-borne encephalitis in children. Vaccine. 2015;33(15):1824-9.
Wittermann, C., Izu, A., Petri, E., Gniel, D., & Fragapane, E. (2015). Five year follow-up after primary vaccination against tick-borne encephalitis in children. Vaccine, 33(15), 1824-9. https://doi.org/10.1016/j.vaccine.2015.02.038
Wittermann C, et al. Five Year Follow-up After Primary Vaccination Against Tick-borne Encephalitis in Children. Vaccine. 2015 Apr 8;33(15):1824-9. PubMed PMID: 25728316.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Five year follow-up after primary vaccination against tick-borne encephalitis in children. AU - Wittermann,Christoph, AU - Izu,Allen, AU - Petri,Eckhardt, AU - Gniel,Dieter, AU - Fragapane,Elena, Y1 - 2015/02/26/ PY - 2014/09/16/received PY - 2015/01/26/revised PY - 2015/02/15/accepted PY - 2015/3/3/entrez PY - 2015/3/3/pubmed PY - 2016/1/16/medline KW - Immunogenicity KW - Pediatric KW - Persistence KW - Primary vaccination KW - TBE KW - Tick-borne encephalitis SP - 1824 EP - 9 JF - Vaccine JO - Vaccine VL - 33 IS - 15 N2 - BACKGROUND: A first tick-borne encephalitis (TBE) vaccine booster in children is currently suggested 3 years after completing either a conventional (doses on Days 0, 28 and 300) or accelerated conventional (doses on Days 0, 14 and 300) TBE immunization schedule. This recommendation, however, may not be appropriate in cases where different TBE vaccines have been used interchangeably during the primary immunization series. METHODS: To provide robust data to better inform such recommendations, TBE antibody persistence was evaluated after 3-5 years in four groups of children (aged 5-15 years): two groups previously primed with three doses of Encepur(®) Children (conventional/accelerated conventional schedule); and two groups previously primed with two doses of FSME-IMMUN(®) followed by a third dose of Encepur(®) Children (conventional/accelerated conventional schedule). Immunogenicity was evaluated using neutralization (NT) assays based on both vaccine antigens as well as on the Enzyme Linked Immunosorbent Assay (ELISA). RESULTS: In the two Encepur(®) Children groups (full series), protective NT titers of ≥10 were detected in 98-100% of children up to 5 years after their last primary vaccination, irrespective of schedule. In contrast, only 65-70% subjects in the FSME-IMMUN(®) Junior groups (mixed series) displayed NT titers ≥10 after 3 years. Thus, due to lower probability of achieving/maintaining long-term protective antibody levels (recently defined by the World Health Organization as an NT titer ≥10) after this time point, both FSME-IMMUN Junior groups were discontinued. CONCLUSION: A strong antibody response persists for at least 5 years after full primary vaccination with Encepur(®) Children. The study thus provides support for extending the time interval for a first booster dose after primary vaccination (conventional/accelerated conventional schedule) with Encepur(®) Children from 3 to 5 years. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/25728316/Five_year_follow_up_after_primary_vaccination_against_tick_borne_encephalitis_in_children_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)00227-3 DB - PRIME DP - Unbound Medicine ER -